What it is
PT-141, also called bremelanotide, is a man-made chain of 7 amino acids (a peptide). It came out of research on Melanotan II but was engineered to be more selective. Melanotan II causes tanning, appetite suppression and sexual effects all at once; PT-141 was built to isolate the sexual function part.
The body has five melanocortin receptors, MC1 through MC5 — these are docking points on cells that respond to certain signals. PT-141 mainly switches on the MC4 receptor, which sits in the brain and helps regulate sexual arousal and desire. It has some activity at MC3 and MC1 too, but the sexual effects come from MC4 in the hypothalamus, a control centre deep in the brain.
This is the key difference from Viagra and Cialis. Those drugs work on blood flow, relaxing the blood vessels of the penis. PT-141 does not work on blood flow at all. It works in the brain, on the desire itself. That is why it works in both men and women, and why it can help people who get nothing from Viagra or Cialis.
It was originally developed by Palatin Technologies, out of Melanotan II research at the University of Arizona in the 1990s, when a researcher accidentally injected twice his intended dose and had an 8-hour erection. In 2019 it was FDA approved under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women. It is not FDA approved for men, though trials in men with erectile dysfunction have been positive and more are ongoing.
It arrives as a dry powder in a sealed glass vial. You add bacteriostatic water (sterile water with a preservative that lets it keep for weeks), then inject it just under the skin — a subcutaneous injection — into the abdomen or thigh, 45 to 60 minutes before sexual activity. A nasal spray version exists and works on similar timing.
PT-141 (bremelanotide) is a synthetic 7-amino-acid melanocortin receptor agonist derived from Melanotan II but re-engineered for selectivity. Where Melanotan II activates the melanocortin family non-selectively — producing tanning, appetite suppression and sexual effects simultaneously — PT-141 isolates the sexual function component.
Of the five melanocortin receptors (MC1–MC5), PT-141 primarily activates MC4R, with residual activity at MC3 and MC1. The sexual effects are driven by hypothalamic MC4R activation.
The mechanistic distinction from PDE5 inhibitors is the whole point. PDE5 inhibitors act peripherally on cavernosal smooth muscle and nitric oxide signalling; PT-141 has no haemodynamic action and operates centrally on desire and arousal. That is why it is active in both sexes and why it retains efficacy in sildenafil non-responders whose failure point is upstream of the vasculature.
Developed by Palatin Technologies from University of Arizona Melanotan II work in the 1990s, following an accidental double dose that produced an 8-hour erection. FDA approved in 2019 as Vyleesi for HSDD in premenopausal women; not approved for men, with Phase 2 ED trials completed and a Phase 2 combination trial with a PDE5 inhibitor underway.
Subcutaneous administration into abdomen or thigh, 45–60 minutes pre-activity. Dosing is episodic and on-demand, bounded by a label ceiling of one dose per 24 hours and 8 doses per month. Note that the older desensitisation rationale for that cap is not well supported by the long-term data: the 52-week open-label extension showed sustained benefit without notable receptor desensitisation (Kingsberg et al., 2019). A nasal route exists on comparable timing.
How it works
PT-141 works through the brain, not the blood vessels.
After the injection it enters the bloodstream and crosses into the brain, where it binds to MC4 receptors concentrated in the hypothalamus — the brain's control centre for sexual arousal. When those receptors are switched on, the brain releases more dopamine in an area called the medial preoptic area. Dopamine is the chemical messenger behind desire, motivation and reward. In effect, PT-141 turns up the volume on the brain's arousal circuitry.
A simple comparison: Viagra and Cialis widen the pipes so more water can flow. PT-141 turns on the tap. If the tap is already running and the problem is purely mechanical, a blood-flow drug handles it. If the tap is barely running — desire and arousal are low — PT-141 addresses the upstream problem those drugs cannot reach.
Because the mechanism is central, PT-141 does not lower blood pressure the way blood-flow drugs do, and it does not rely on nitric oxide in the vessels. In men, this means it can produce erections even where Viagra or Cialis have failed, because the failure may be in the brain rather than in the plumbing.
In women it activates the same MC4 receptors and raises dopamine-driven arousal signalling, which shows up as more desire, better arousal and greater satisfaction. The mechanism does not depend on hormone levels, so it works in premenopausal women whatever their oestrogen or testosterone readings.
Timing: after a subcutaneous injection, blood levels peak at about 1 hour. The peptide clears from the blood fairly quickly — it is broken down by having its peptide bonds split, and is removed roughly 65% through urine and 23% through faeces — but the effect outlasts the clearance. Effects on sexual function can begin within 45 minutes and last up to 12 to 24 hours, with some users reporting effects persisting up to 72 hours at higher doses. Absorption from a subcutaneous injection is essentially complete.
Subcutaneous PT-141 enters circulation and crosses into the CNS, binding MC4 receptors concentrated in the hypothalamus. Downstream of MC4R activation, dopamine release increases in the medial preoptic area — the dopaminergic substrate of desire, motivation and reward. Functionally, MC4R agonism amplifies gain in the central arousal circuit.
The contrast with PDE5 inhibition is categorical: PDE5 inhibitors widen the conduit, PT-141 opens the tap. Where the limiting lesion is haemodynamic, a PDE5 inhibitor suffices; where the limiting lesion is central arousal, PT-141 addresses what PDE5 inhibitors cannot.
The central mechanism also explains the pressure profile. PT-141 does not produce the hypotensive effect of PDE5 inhibitors and is independent of vascular nitric oxide signalling; instead it causes a small transient pressor effect. In men this permits erectile response in PDE5 non-responders, since the failure point may be supraspinal rather than vascular.
In women the same MC4R population is engaged, increasing dopamine-mediated arousal signalling and translating to increased desire, improved arousal response and greater satisfaction. Efficacy is independent of hormonal status, which is why it works in premenopausal women irrespective of oestrogen or testosterone levels.
Pharmacokinetics: Tmax approximately 1 hour after subcutaneous injection; half-life approximately 2.7 hours; subcutaneous bioavailability essentially 100%. Metabolised by hydrolysis of peptide bonds, excreted roughly 65% renally and 23% faecally. Pharmacodynamic duration substantially exceeds plasma exposure — onset within 45 minutes, effects lasting up to 12 to 24 hours, with some users reporting persistence up to 72 hours at higher doses.
What it does
Desire and arousal: it stimulates the melanocortin system in the brain, which regulates sexual arousal. The result is a marked increase in libido and a stronger physical arousal response. Users also report stronger orgasms. This matters most for people whose problem is low desire rather than, or as well as, physical dysfunction.
In men: it improves erection quality. In clinical trials it produced clinically meaningful erections in men with erectile dysfunction, including men who did not respond to sildenafil (Viagra). One study showed a 33.5% success rate in achieving erections in sildenafil non-responders compared with 8.5% on placebo. Effects begin within 30 to 45 minutes and can last several hours.
In women: it treats hypoactive sexual desire disorder — persistently low sexual desire not explained by another medical or psychiatric condition, relationship problems or medication — in women before the menopause. It is the only FDA-approved injectable treatment for this. The Phase 3 RECONNECT trials showed significant improvements in sexual desire, less distress about low desire, and more satisfying sexual events.
Independent of hormones: because it works through the melanocortin pathway rather than sex hormones, it does not depend on testosterone or oestrogen levels. That makes it an option for people with normal hormone panels who still have low desire.
Sensation and confidence: it heightens genital sensitivity, reduces sexual anxiety and improves sexual confidence. Performance anxiety often drops as a knock-on effect of better arousal rather than being treated directly.
Practical differences from the alternatives: it is non-invasive apart from the injection, longer-lasting than some alternatives, and the older material notes no adverse reaction with alcohol. Side effects differ rather than simply being fewer — nausea is common, and there is a small temporary rise in blood pressure.
Central MC4R agonism regulating sexual arousal, producing marked libido enhancement, improved physical arousal response and increased orgasmic response. Most useful where the deficit is desire rather than purely mechanical.
Male erectile function: clinically meaningful erections in men with ED, including sildenafil non-responders — 33.5% success rate in achieving erections versus 8.5% on placebo. Onset 30 to 45 minutes, duration several hours. The Phase 2 data (Diamond et al., 2004) showed erections exceeding 80% tip rigidity lasting more than 40 minutes on 1.25 to 2 mg subcutaneously, with 68% of responders reporting increased sexual desire versus 19% on placebo. Erectile benefit here is downstream of central arousal, not haemodynamic, so it is complementary to rather than competing with a PDE5 inhibitor.
Female indication: HSDD in premenopausal women, the approved indication and the only FDA-approved injectable for it. RECONNECT Phase 3 demonstrated statistically significant improvement in sexual desire scores, reduced desire-related distress and increased frequency of satisfying sexual events (Clayton et al., 2019).
Hormonal independence: efficacy via the melanocortin pathway rather than sex steroids means no dependence on testosterone or oestrogen status — viable in subjects with normal panels and persistent low desire.
Sensory and psychological: heightened genital sensitivity; reduced sexual anxiety and improved confidence; performance anxiety reduced secondary to improved arousal rather than as a primary effect.
Comparative profile: non-invasive beyond the injection itself, longer-lasting effects than some alternatives, and per the earlier material no adverse interaction with alcohol. The side effect trade is real rather than favourable across the board — nausea in approximately 40% of Phase 3 participants, plus a transient pressor effect of approximately 2 to 3 mmHg systolic and diastolic.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Increases genuine sexual desire, not just physical capability — it works on the brain's arousal circuitry.Human trials
- Produces a marked increase in libido and stronger orgasmic response.Human trials
- Improves erection quality, including in men who do not respond to Viagra — 33.5% success rate in sildenafil non-responders versus 8.5% on placebo.Human trials
- Treats hypoactive sexual desire disorder in women before the menopause, the only FDA-approved injectable for it, with Phase 3 RECONNECT showing better desire, less distress and more satisfying sexual events.Human trials
- Works regardless of hormone levels, so it is an option for people with normal testosterone or oestrogen who still have low desire.Limited human data
- Heightens genital sensitivity.Anecdotal
- Reduces sexual anxiety and improves confidence.Anecdotal
- Reduces performance anxiety, as a knock-on effect of better arousal.Anecdotal
- Longer-lasting effects than some other treatments — often 6 to 12 hours, sometimes longer.Anecdotal
- A non-invasive option apart from the injection itself.Anecdotal
- Does not react badly with alcohol.Limited human data
- Does not lower blood pressure the way Viagra and Cialis do.Limited human data
- Central MC4R-driven increase in desire and arousal rather than purely peripheral capability.Human trials
- Marked libido enhancement with increased orgasmic response.Human trials
- Improves erectile quality secondary to central arousal, with efficacy retained in PDE5 non-responders — 33.5% versus 8.5% placebo.Human trials
- Approved treatment for HSDD in premenopausal women; RECONNECT Phase 3 (Clayton et al., 2019) showed significant gains in desire score, reduced desire-related distress and increased satisfying sexual events.Human trials
- Efficacy independent of hormonal status — no dependence on oestrogen or testosterone, making it viable alongside or instead of hormonal intervention.Limited human data
- Heightened genital sensitivity.Anecdotal
- Reduced sexual anxiety with improved confidence.Anecdotal
- Performance anxiety reduced secondary to improved arousal.Anecdotal
- Duration commonly 6 to 12 hours with residual desire reported to 24 to 72 hours, longer than several alternatives.Anecdotal
- Non-invasive beyond subcutaneous administration.Anecdotal
- No adverse interaction with alcohol — a practical advantage over PDE5 inhibitors.Limited human data
- No hypotensive effect and no dependence on vascular nitric oxide signalling, unlike PDE5 inhibitors.Limited human data
- Long-term extension data (Kingsberg et al., 2019) showed sustained benefit over 52 weeks without notable receptor desensitisation.Limited human data
What to expect
PT-141 is taken as needed, not every day. Effects usually begin 45 minutes to 1 hour after the injection. They peak at 1 to 3 hours. Many people report effects lasting 6 to 12 hours, and some report residual improvement in desire for up to 24 to 72 hours.
From the clinical trials, the most consistent finding is more subjective sexual desire and a better arousal response. In men, both spontaneous and responsive erections improve. In women, the main gains are in desire and satisfaction rather than one specific physical response.
From forums and user communities, men commonly report libido rising about 1 hour after injection, better erection quality and greater sexual sensitivity. Women report feeling more mentally engaged during sex and more physically aroused. Both sexes commonly say the effect feels more natural than pharmaceutical alternatives, because it raises actual desire rather than just the physical response.
One thing to plan for: the nausea is real. About 40% of people in the clinical trials reported nausea, typically starting about 1 hour after injection and lasting about 2 hours. Most describe it as mild, but for some it is bad enough to be unpleasant. Taking the dose before bed, or using an anti-sickness medicine such as ondansetron, can help. Starting low and working up is the usual way to find a dose that works without too much nausea.
It will not usually give an erection out of nowhere the way Melanotan II can. Most men report becoming more responsive to sexual cues rather than getting spontaneous erections.
On-demand dosing, not daily. Onset 45 minutes to 1 hour post-injection, peak at 1 to 3 hours, sustained effects commonly 6 to 12 hours, with residual desire reported to 24 to 72 hours.
Trial-derived findings: the most consistent signal is increased subjective sexual desire and improved arousal response. In men, both spontaneous and responsive erections improve. In women, gains concentrate in desire and satisfaction rather than a discrete physical endpoint.
Anecdotal reports from external platforms: men describe libido onset around 1 hour, improved erection quality and increased sexual sensitivity, with libido elevation over 12 to 24 hours. Women describe greater mental engagement and heightened physical arousal. Both sexes commonly characterise the response as more natural than PDE5 inhibitors because the desire itself is raised rather than just the mechanics. Negative reports centre on nausea, with a subset describing it as severe enough to limit willingness to use; flushing, facial warmth, mild fatigue and headache also feature, and some men report uncomfortably persistent erections at higher doses reminiscent of Melanotan II.
Nausea is the dominant tolerability issue: approximately 40% in Phase 3, median onset about 1 hour post-dose, median duration about 2 hours, usually mild. Bedtime dosing or ondansetron pre-treatment mitigates it. Reported dosing in practice reflects this — most users settle on the minimum effective dose, since higher doses give stronger effects and more nausea.
Spontaneous erection is not the typical presentation at standard doses. The practical effect is heightened responsiveness to sexual cues rather than unprovoked tumescence.
Reconstitution and dosing
Studied doses. The FDA-approved dose for women with hypoactive sexual desire disorder is 1.75 mg under the skin, self-injected at least 45 minutes before expected sexual activity, with no more than one dose per 24 hours and no more than 8 doses per month. In men with erectile dysfunction, Phase 2 trials used 1.25 to 2 mg under the skin, and it worked across that range. There are no published dose-finding studies for the off-label doses men commonly use for libido, so the practical protocol below comes from clinical practice patterns and usual practice rather than trial data.
Mixing. The vial holds 10 mg of dry powder. Add 2 mL of bacteriostatic water. That gives 500 micrograms per 10 units on an insulin syringe, so 1 mg = 20 units, 1.75 mg = 35 units, and 2 mg = 40 units. Add the water slowly down the inside wall of the vial and swirl gently — do not shake.
Standard use. 1 to 2 mg injected under the skin of the abdomen or thigh, as needed, 45 to 60 minutes before sexual activity. Start at the lower end and only move up if you need to.
If nausea is a problem. Start at 0.5 mg for the first use. Then try 0.75 mg, then 1 mg on later occasions. The aim is the lowest dose that works with nausea you can live with. Ondansetron (Zofran) taken 30 minutes beforehand can reduce nausea, as can dosing before bed.
Tolerance test. Some users take 500 micrograms (10 units) on an ordinary day, not before an actual encounter, purely to check the body tolerates the peptide before a full dose. It is not expected to do much for sexual activity.
Limits. No more than one dose in any 24 hours. No more than 8 doses in a month — at 2 mg that is 16 mg total. Earlier material treated 2.5 mg (50 units) as an absolute maximum, only for people who have already tolerated the standard dose, and never to be exceeded. The monthly cap comes from the FDA label. The concern about the melanocortin system becoming less responsive with heavy long-term use is one reason people cap frequency, though the 52-week extension study found benefits held up without notable loss of response.
Studied doses. FDA-approved dose for HSDD in premenopausal women: 1.75 mg subcutaneously, self-administered at least 45 minutes before anticipated sexual activity, maximum one dose per 24 hours and 8 doses per month. Male ED Phase 2 trials used 1.25 to 2 mg subcutaneously with efficacy demonstrated across the range. No published dose-finding studies exist for the off-label subcutaneous protocols used by men for libido enhancement; the practical protocol reflects clinical practice patterns and usual practice.
Reconstitution. 10 mg vial with 2 mL bacteriostatic water yields 500 mcg per 10 units on an insulin syringe: 1 mg = 20 units, 1.75 mg = 35 units, 2 mg = 40 units. Earlier material gives 2.5 mg = 50 units at the same concentration. Diluent down the vial wall, swirl, do not shake.
Standard protocol. 1 to 2 mg subcutaneously into abdomen or thigh, as needed, 45 to 60 minutes pre-activity. No cycle in the conventional sense — episodic on-demand dosing bounded by a monthly cap.
Nausea-sensitive titration. 0.5 mg first use, then 0.75 mg, then 1 mg on subsequent uses, targeting the minimum effective dose with tolerable nausea. Ondansetron 30 minutes prior reduces nausea; bedtime administration is an alternative mitigation. Reported practice mirrors this, with many starting at 0.5 to 1 mg to gauge tolerance before moving to 1.5 to 2 mg, and dose-dependent nausea driving most users to settle low.
Tolerance test. A 500 mcg (10 units) non-therapeutic test dose on a non-encounter occasion is used by some to establish tolerance before a full dose; if adverse effects occur at that level, titrate incrementally rather than escalating directly.
Ceilings. One dose per 24 hours; 8 doses per month (16 mg total at 2 mg per dose). Earlier material sets an absolute maximum of 2.5 mg (50 units), reserved for subjects who have established tolerance to the standard dose and not to be exceeded. The monthly ceiling derives from the FDA label. The melanocortin desensitisation rationale sometimes cited for frequency limits is not strongly supported: the 52-week open-label extension showed sustained benefit without notable receptor desensitisation (Kingsberg et al., 2019).
Standard, 10 mg vial
Mix with 2 mL (200 units) of bacteriostatic water.
5 mg/mL · 50 mcg per unit
Cycle: No fixed cycle — dosed as needed. No more than one dose per 24 hours and no more than 8 doses per month · Frequency: Subcutaneous injection (abdomen or thigh), 45–60 minutes before sexual activity
| When | Dose | Draw | How often |
|---|---|---|---|
| Starting (20 units) | 1 mg | 20 units | as needed, max 1 dose/24 hours |
| Full (40 units) | 2 mg | 40 units | as needed, max 1 dose/24 hours |
Alternative protocols
Alternative protocols reflect older community practice and are kept for reference.
Alternative, 10 mg vial
Mix with 2 mL (200 units) of bacteriostatic water.
5 mg/mL · 50 mcg per unit
Cycle: No fixed cycle — dosed on demand. Never more than 1 injection in 24 hours, and never more than 8 doses in a month · Frequency: Inject 45–60 minutes before sexual activity
| When | Dose | Draw | How often |
|---|---|---|---|
| Initial dose — tolerance test only, not effective for sexual activity; take on an ordinary day (10 units) | 500 mcg | 10 units | once, before starting |
| Standard dose (40 units) — max 8 doses / 16 mg per month | 2 mg | 40 units | 45–60 minutes before sex; max 1×/24 hours |
| Maximum dose (50 units) — only after building tolerance to the standard dose; never exceed | 2.5 mg | 50 units | 45–60 minutes before sex; max 1×/24 hours, 8 doses/month |
10 mg in 2 mL is 5 mg/mL, or 50 mcg per unit. Draw 20 units (0.2 mL) for 1000 mcg.
Who should avoid it
- Do not use it if you have high blood pressure that is not under control, or significant heart or blood vessel disease.
- Do not use it if you have ever reacted badly to bremelanotide or to anything else in the product.
- Be careful if your high blood pressure is controlled — check your blood pressure if you use it, because PT-141 raises it slightly for a few hours.
- Be careful if your liver or kidneys do not work properly. It has not been studied in either case.
- Do not use it in pregnancy or while breastfeeding. There is no safety data.
- Avoid it in any condition where a short rise in blood pressure could be dangerous.
- Take care with any other medicine that affects blood pressure.
- If you take naltrexone by mouth, PT-141 may make it work less well. The official label advises against using the two together.
- Stick to the frequency limits. No more than one dose in 24 hours, and no more than 8 doses in a month.
- If dizziness and blurred vision happen at the same time, see a doctor immediately. That combination may point to something more serious.
- Absolute: uncontrolled hypertension or significant cardiovascular disease.
- Absolute: known hypersensitivity to bremelanotide or any component of the formulation.
- Caution: controlled hypertension — monitor blood pressure, given the transient mean rise of approximately 2 to 3 mmHg systolic and diastolic peaking 4 to 8 hours post-dose.
- Caution: hepatic impairment — not studied.
- Caution: renal impairment — not studied.
- Caution: pregnancy or breastfeeding — no safety data.
- Caution: any condition in which a transient blood pressure increase could be hazardous.
- Interaction: concomitant agents affecting blood pressure warrant caution.
- Interaction: PT-141 may reduce the effectiveness of oral naltrexone; the FDA label recommends against concurrent use.
- Frequency ceilings per the FDA label: no more than 1 dose per 24 hours and no more than 8 doses per month. Earlier practice guidance framed these as melanocortin desensitisation control, though the 52-week open-label extension reported sustained benefit without notable receptor desensitisation.
- Red flag: concurrent dizziness and blurred vision warrants immediate physician consultation.
Side effects
- Nausea is the main one — about 40% of people in the Phase 3 trials had it. It usually starts about 1 hour after the injection and lasts about 2 hours. Most describe it as mild, but for some it is bad enough to put them off using it.
- Flushing — warmth or redness in the face — in about 20%.
- Reactions where you inject, such as redness, swelling, itching or soreness, in 13%.
- Headache in 11%.
- Vomiting in 4.8%, cough in 3.3%, tiredness in 3.2%, hot flushes in 2.7%, tingling in 2.6%, dizziness in 2.2%, and a blocked nose in 2.1%.
- A small, short rise in blood pressure of about 2 to 3 mmHg, highest 4 to 8 hours after the dose and back to normal by 12 to 24 hours. No serious blood pressure events happened in the trials.
- Darkening of the skin in about 1% of trial participants. No cases of melanoma have been reported with PT-141.
- Users also report joint pain or swelling, blurred vision, and erections that feel uncomfortably persistent at higher doses.
- Most effects depend on the dose and pass on their own. Taking it before bed, or using an anti-sickness medicine such as ondansetron, can help with the nausea.
- If dizziness and blurred vision happen together, see a doctor immediately.
- Nausea: approximately 40% of Phase 3 participants, median onset about 1 hour post-dose, median duration about 2 hours. Commonly described as mild but the principal deterrent in practice.
- Flushing: approximately 20%.
- Injection site reactions: 13% — redness, swelling, itching or soreness.
- Headache: 11%.
- Vomiting 4.8%, cough 3.3%, fatigue 3.2%, hot flushes 2.7%, paraesthesia 2.6%, dizziness 2.2%, nasal congestion 2.1%.
- Transient pressor effect: mean increase approximately 2 to 3 mmHg systolic and diastolic, peaking 4 to 8 hours post-dose, returning to baseline by 12 to 24 hours. No significant hypertensive events in the clinical trials, but relevant in uncontrolled hypertension.
- Hyperpigmentation: approximately 1% of Phase 3 participants. No melanoma cases reported with PT-141.
- Also reported: joint pain or swelling, blurred vision, and uncomfortably persistent erections in men at higher doses — the latter echoing Melanotan II reports.
- Most effects are dose-dependent and self-limiting. Ondansetron 30 minutes prior, or evening dosing, mitigates nausea.
- Concurrent dizziness and blurred vision warrants immediate physician consultation.
What the evidence shows
PT-141 has better evidence than most research peptides because it went through the full FDA approval process for one use. In 2019 it was approved under the brand name Vyleesi for low sexual desire in women before the menopause.
The RECONNECT trials were two identical studies in which neither the participants nor the researchers knew who got the real drug. They enrolled 1,247 premenopausal women with low sexual desire. Women injected either 1.75 mg of PT-141 or a placebo, as needed before sex, for 24 weeks. Both trials showed a real improvement in desire scores and more satisfying sexual events than placebo. A 52-week follow-up study showed the benefit kept going, without the drug losing its effect (Clayton et al., 2019, Obstetrics and Gynecology).
In men, a Phase 2 study used 1.25 to 2 mg under the skin in men who had already failed Viagra-type drugs. Measuring devices recorded erections over 80% tip firmness lasting more than 40 minutes, and 68% of the men who responded said their sexual desire went up, against 19% on placebo (Diamond et al., 2004, International Journal of Impotence Research). Another study reported a 33.5% success rate for erections in men who did not respond to sildenafil, compared with 8.5% on placebo.
A Phase 2 trial is currently running on PT-141 combined with a Viagra-type drug in one formulation, to hit both the brain side and the blood flow side at once.
On safety, the trials found only a small short-lived rise in blood pressure of about 2 to 3 mmHg, highest 4 to 8 hours after the dose and back to normal by 12 to 24 hours. That does not matter for most people but it does matter if blood pressure is not controlled.
There are no published dose-finding studies for the off-label doses men commonly use for libido.
PT-141 carries stronger clinical evidence than most peptides, having completed full FDA approval for hypoactive sexual desire disorder in premenopausal women (Vyleesi, 2019).
The RECONNECT Phase 3 programme comprised two identical randomised, double-blind, placebo-controlled trials enrolling 1,247 premenopausal women with HSDD. Participants received 1.75 mg PT-141 or placebo subcutaneously as needed before anticipated sexual activity for 24 weeks. Both trials showed statistically significant improvement in sexual desire scores and a meaningful increase in satisfying sexual events versus placebo. A 52-week open-label extension showed sustained benefit without notable receptor desensitisation (Clayton et al., 2019, Obstetrics and Gynecology).
In men with erectile dysfunction, a Phase 2 study of subcutaneous PT-141 at 1.25 to 2 mg produced clinically meaningful erections in PDE5 inhibitor non-responders. Rigidity monitoring recorded erections exceeding 80% tip rigidity lasting more than 40 minutes, and 68% of responders reported increased sexual desire versus 19% on placebo (Diamond et al., 2004, International Journal of Impotence Research). A separate analysis reported a 33.5% erection success rate in sildenafil non-responders versus 8.5% on placebo.
A Phase 2 study is underway on a co-formulation of PT-141 with a PDE5 inhibitor, targeting the central desire pathway and the peripheral vascular pathway simultaneously.
Safety data show a small transient pressor effect — mean 2 to 3 mmHg systolic and diastolic, peaking 4 to 8 hours post-dose and resolving by 12 to 24 hours — clinically insignificant for most but relevant in uncontrolled hypertension.
The FDA-approved dose for women is 1.75 mg subcutaneously at least 45 minutes before anticipated activity, capped at one dose per 24 hours and 8 doses per month. No published dose-finding studies exist for the off-label subcutaneous protocols used by men for libido enhancement.
User reports
From public forums
These reports are gathered from Reddit, Excel Male forums, peptide communities and clinic testimonials. They are anecdotes, not research, so treat them as weaker evidence than the trials.
The most common positive comment is that PT-141 feels more natural than Viagra-type drugs, because it raises genuine desire rather than just physical ability. Men report better erection quality, higher libido for 12 to 24 hours, and more sensitivity during sex. Women report stronger mental arousal, more spontaneous desire, and greater satisfaction. Both sexes report feeling more mentally engaged.
The main complaint is nausea, which matches the trial data. Some describe flushing, warmth in the face and mild tiredness. A subset say the nausea is bad enough that they stop wanting to use it. Some men say the erections can feel uncomfortably persistent, similar to what Melanotan II users describe. A small number report headaches.
On dosing, most users report 1 to 2 mg under the skin. Many start at 0.5 to 1 mg to see how much nausea they get before moving up to 1.5 to 2 mg. Most inject 1 to 2 hours before sex. Some use it once or twice a week. Higher doses generally give stronger effects and more nausea, so most people settle on the smallest dose that works for them.
Aggregated from external platforms including Reddit, Excel Male forums, peptide communities and clinic testimonials. Anecdotal and lower-weight than published data.
Positive reports centre on a subjectively more natural sexual response than PDE5 inhibitors, described as an increase in genuine desire rather than physical capability alone. Men report improved erection quality, elevated libido for 12 to 24 hours, and greater sensitivity during intercourse. Women report increased mental arousal, more frequent spontaneous desire, and greater satisfaction.
Negative reports are dominated by nausea, consistent with trial incidence. Flushing, facial warmth and mild fatigue are also common. A subset report nausea severe enough to limit willingness to continue. Some men describe uncomfortably persistent erections, paralleling Melanotan II reports. Headache is reported by a minority.
Dosing patterns in practice: most report 1 to 2 mg subcutaneously, with many starting at 0.5 to 1 mg to gauge nausea tolerance before moving to 1.5 to 2 mg. Injection 1 to 2 hours before anticipated activity is common, and some report once or twice weekly use. Dose-response for both efficacy and nausea is reported consistently, with most settling on the individual minimum effective dose.
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
The same peptide as a nasal spray, on similar pre-dose timing. Use one form or the other — the limit of 8 doses a month covers both together, not 8 of each.
Same molecule, same pre-dose window, no needle. The 8-doses-per-month ceiling is a property of the compound and its label, not of a route — count doses across both forms together.
- PDE5 inhibitors (Viagra, Cialis)
This is the combination being tested in trials right now. PT-141 works on desire in the brain; Viagra and Cialis work on blood flow in the penis. Different systems, so they can add up. Both can affect blood pressure, so watch for lightheadedness or dizziness. Most useful for men who have both low desire and a physical erection problem.
Currently under evaluation as a co-formulation in a Phase 2 trial. PT-141 acts centrally on the MC4-dopamine arousal pathway; PDE5 inhibitors act peripherally on nitric oxide-mediated cavernosal smooth muscle relaxation. Fully independent pathways. Shared consideration is blood pressure — monitor for lightheadedness or dizziness. Most relevant in men with concurrent low desire and mechanical ED.
- TRT
No interaction concerns. PT-141 works through a different system to testosterone. If libido is still low on TRT, PT-141 addresses a different mechanism entirely.
No interaction concerns. Melanocortin receptor signalling is independent of androgen receptor signalling. Appropriate adjunct where libido remains low despite adequate androgen replacement.
Adds connection, bonding and emotional intimacy alongside PT-141's effect on desire.
Oxytocinergic bonding and emotional intimacy alongside melanocortin-driven arousal — genuinely distinct receptor systems, so combination effects do not overlap.
No interaction concerns, and it supports recovery, energy and general hormone balance alongside the libido benefit. Growth hormone peptides need a fasted window; PT-141 does not, so there is no scheduling clash.
No interaction concerns — different pathways and different timing requirements. GH secretagogues require a fasted window; PT-141 does not, so no scheduling conflict. GH-axis support for recovery, energy and hormone optimisation complements rather than duplicates the libido effect.
- Kisspeptin
No known interaction. Kisspeptin acts on the hormone chain that drives testosterone production; PT-141 acts on the brain's arousal system. They cover different parts of sexual health.
No known interaction. Kisspeptin acts on the HPG axis to stimulate GnRH and downstream testosterone production; PT-141 acts on the melanocortin system. Complementary coverage of distinct aspects of sexual function.
General tissue recovery and performance support, especially for physically active users. No overlap with what PT-141 does.
General tissue recovery and performance support, particularly in physically active subjects. No mechanistic overlap with melanocortin signalling.
Grouped with BPC-157 for tissue recovery and performance support.
Grouped with BPC-157 for tissue recovery and performance support; no melanocortin overlap.
- Vitamin B12
Suggested for energy, and reported to help reduce the nausea PT-141 commonly causes.
Suggested for energy support and reported reduction of nausea, which is the dominant adverse effect at approximately 40% incidence in Phase 3 trials.
- Melanotan-2
Do not stack these. Melanotan II already switches on the same brain receptor PT-141 targets, so adding PT-141 on top is pointless at best and raises the risk of nausea and blood pressure changes at worst. If Melanotan II is already giving the sexual benefits, PT-141 is not needed.
Not recommended. Melanotan II already activates MC4R as part of its non-selective melanocortin activity, making PT-141 redundant on top of it and compounding nausea and pressor risk. Where Melanotan II is already delivering the sexual function benefit, PT-141 adds nothing. Older practice guidance paired the two for libido, skin tone and confidence; the mechanistic overlap argues against it.
Common questions
How is PT-141 different from Viagra?
Completely different mechanism. Viagra works on blood flow in the penis. PT-141 works in the brain and increases sexual desire. Viagra fixes the plumbing; PT-141 turns on the tap.
Entirely different mechanism. Sildenafil inhibits PDE5, relaxing cavernosal smooth muscle and increasing blood flow peripherally. PT-141 activates central MC4 receptors in the hypothalamus, increasing dopamine release in the medial preoptic area and raising desire and arousal. One addresses vascular mechanics, the other the upstream arousal circuitry.
Does PT-141 work for women?
Yes. It is FDA approved specifically for women with low sexual desire that has no other explanation. The Phase 3 trials showed real improvements in desire, arousal and satisfaction. It works through the same brain pathway in both sexes.
Yes — it is FDA approved for hypoactive sexual desire disorder in premenopausal women. The Phase 3 RECONNECT trials demonstrated significant improvements in desire, arousal and satisfaction. The central MC4 pathway is the same in both sexes, and efficacy does not depend on oestrogen or testosterone status.
How fast does it work and how long does it last?
Effects start within 45 minutes to 1 hour after the injection and peak at 1 to 3 hours. Many people feel it for 6 to 12 hours, and some report leftover improvement in desire for 12 to 72 hours.
Peak plasma concentration at about 1 hour post-injection with a half-life of approximately 2.7 hours and essentially 100% subcutaneous bioavailability. Functional onset within 45 minutes, peak effect at 1 to 3 hours, sustained effects commonly 6 to 12 hours, with residual desire reported up to 24 to 72 hours at higher doses.
Does it need to be taken every day?
No. It is used only when needed, not daily. The official label limits it to no more than once in 24 hours and no more than 8 times a month.
No — dosing is episodic and on-demand. The FDA label caps use at one dose per 24 hours and 8 doses per month.
Will it cause an erection out of nowhere?
Not usually at standard doses, the way Melanotan II can. It increases desire and how strongly you respond to arousal. Most men report being more responsive to sexual cues rather than getting spontaneous erections.
Not typically at standard doses, in contrast to Melanotan II reports. The effect is an increase in desire and in the arousal response to stimulation rather than spontaneous tumescence, though some men using higher doses report uncomfortably persistent erections.
Can it be used if Viagra does not work?
That is exactly the group it was designed for. If Viagra-type drugs do not help, the problem may be in the brain's arousal circuitry rather than the blood vessels, and PT-141 addresses that. One study found a 33.5% erection success rate in men who did not respond to sildenafil, against 8.5% on placebo.
This is the target population. PDE5 non-response suggests the limiting factor may be upstream central arousal rather than downstream haemodynamics. A 33.5% erection success rate was reported in sildenafil non-responders versus 8.5% on placebo, and Phase 2 data in PDE5 failures showed erections exceeding 80% tip rigidity lasting more than 40 minutes (Diamond et al., 2004).
What can be done about the nausea?
Nausea is the most common side effect — about 40% of trial participants had it, starting about an hour after the dose and lasting about 2 hours. Taking the dose before bed helps. So does an anti-sickness medicine such as ondansetron, taken 30 minutes beforehand. Nausea-sensitive users can also start at 0.5 mg, then 0.75 mg, then 1 mg on later occasions to find the smallest dose that works.
Nausea affected approximately 40% of Phase 3 participants, with median onset about 1 hour post-dose and median duration about 2 hours. Mitigation options: evening or pre-sleep dosing, ondansetron 30 minutes prior, and upward titration from 0.5 mg to 0.75 mg to 1 mg across successive uses to establish the minimum effective dose with tolerable nausea. Nausea is dose-dependent.
Does the melanocortin system stop responding with repeated use?
The 52-week follow-up study in women showed the benefit kept going without the drug losing effect. Even so, the label limits stay at one dose in 24 hours and 8 doses a month, and it is sensible to stay within them.
The 52-week open-label extension reported sustained benefit without notable receptor desensitisation, which tempers the older concern that frequent use erodes MC4R responsiveness. The label ceilings of one dose per 24 hours and 8 doses per month still apply and remain the practical bound on frequency.
References
- Clayton AH, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and Gynecology. 2019;134(5):899-908.
- Kingsberg SA, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics and Gynecology. 2019;134(5):909-917.
- Clayton AH, et al. Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial. Women's Health. 2016;12(3):325-337.
- Diamond LE, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. Journal of Sexual Medicine. 2006;3(4):628-638.
- Rosen RC, et al. Melanocortins in the treatment of male and female sexual dysfunction. Current Topics in Medicinal Chemistry. 2007;7(11):1137-1144.
- Pfaus JG, et al. Bremelanotide: an overview of preclinical CNS effects on female sexual function. Journal of Sexual Medicine. 2007;4 Suppl 4:269-279.
- Shin YC, et al. Novel Emerging Therapies for Erectile Dysfunction. World Journal of Men's Health. 2021;39(1):44-64.
This entry has been reviewed and expanded with additional reference material. Units are recomputed from the stated protocol.